T3 Defense (DFNS) Registration filing summary

Company overview and business model

• Strategic acquirer and operator of aerospace and defense businesses, targeting Tier 2 and Tier 3 suppliers in the U.S., Israel and Europe, with emphasis on dual-use technology, AI and critical manufacturing.

• Portfolio includes Star 26/Rimon defense generators and systems, Tiltan defense AI and simulation software, Nimbus UAVs, and a 51% interest in ITS/Positech engineering and motion-control businesses.

• Blade Ranger agreement grants exclusive U.S. defense and homeland-security distribution rights for drone payloads, with minimum purchases of 5, 10 and 15 units in Years 1–3; Mandragola JV holds a 51% stake and targets Baltic and Israeli aviation infrastructure.

• Acquisition strategy emphasizes controlling stakes in smaller businesses, operational improvement and add-on acquisitions; management expects to fund acquisitions primarily through equity and debt offerings.

Financial performance and metrics

• H1 2026 revenue was $7.649M vs. $0 in H1 2025; gross profit was $1.384M and operating expenses were $8.573M vs. $2.555M YoY.

• H1 2026 net loss was $107.780M vs. net income of $105.977M in H1 2025; warrant-liability fair-value loss was $107.641M vs. a $109.406M gain YoY.

• June 30, 2026 cash was $4.085M; net cash used in operations was $9.781M in H1 2026, and projected operating needs for the next 12 months were $5M.

• June 30, 2026 negative working capital was ~$131M, including $124M of warrant liabilities that do not require cash settlement; stockholders’ deficit was $19.659M.

• FY2025 operating revenue was $0 and operating expenses were $32.6M; reported net income of $78.631M included substantial noncash warrant fair-value gains.

Use of proceeds and capital allocation

• Selling stockholders receive all proceeds from resales; no proceeds accrue from those sales. Cash exercise of all Common Warrants issued as of the prospectus date could yield ~$15M, with no assurance of exercise.

• Cash warrant-exercise proceeds are intended for working capital and general corporate purposes; a portion may support complementary acquisitions, with no current commitment to those uses.

• Registration expenses are borne by the registrant; selling stockholders bear commissions, discounts and similar sale expenses.